Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glassia

- PMLiVE

LinkedIn adds a pharma ‘influencer’

Pfizer CEO Ian Read joins the likes of Bill Gates and Richard Branson in writing for the social network

- PMLiVE

EMA and FDA create pharmacovigilance ‘cluster’

Monthly meetings to discuss key issues in medicines safety

- PMLiVE

FDA mulls use of side effect voiceover in TV advertising

Agency considers updating how drug risks are communicated

- PMLiVE

FDA approves Chelsea’s rare blood pressure drug

US biopharma company gets green light in US for Northera

- PMLiVE

US and Indian regulators forge closer ties

FDA signs new agreement with India's Ministry of Health and Family Welfare

- PMLiVE

FDA backs BioMarin drug for rare enzyme disorder

Vimizim is first drug approved in US under rare paediatric disease priority review

- PMLiVE

FDA knocks back J&J and Bayer’s Xarelto in ACS

Follows unanimous negative committee vote

- PMLiVE

FDA knocks back Durect’s painkiller

Regulator wants more safety information for Posidur

- PMLiVE

Shire to file Vyvanse for binge-eating in Q3

Wants to mirror drug’s success as ADHD treatment

- PMLiVE

FDA clears J&J’s Imbruvica for leukaemia

Adds to cancer drug's lymphoma indication

- PMLiVE

FDA to review safety of AZ’s saxagliptin

Diabetes drug linked to heart failure

- PMLiVE

Shire’s ADHD drug fails in depression trial

Company drops Vyvanse for use in major depressive disorder

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links